clofazimine has been researched along with itraconazole in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 3 (25.00) | 29.6817 |
| 2010's | 7 (58.33) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Casciano, CN; Clement, RP; Johnson, WW; Wang, EJ | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Doak, AK; Prusiner, SB; Shoichet, BK; Wille, H | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF | 1 |
| Mundell, AC | 1 |
| Chrusciak Talhari, A; Fischer, M; Reinel, D; Talhari, S | 1 |
| Apte, G; Ganapathi, R; Gedam, JR; Nagpur, NG; Pai, VV; Poojary, S | 1 |
| Beltrame, A; Bisoffi, Z; Danesi, P; Farina, C; Orza, P; Perandin, F; Rodari, P; Staffolani, S; Zanardello, C | 1 |
| Aguilar, CR; Araújo, MG; Cirilo, NS; Guedes, ACM; Santos, SNMBD | 1 |
2 review(s) available for clofazimine and itraconazole
| Article | Year |
|---|---|
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells | 2022 |
New therapeutic agents in veterinary dermatology.
Topics: 4-Quinolones; Animals; Anti-Infective Agents; Cat Diseases; Cats; Chlorambucil; Clofazimine; Dog Diseases; Dogs; Itraconazole; Ivermectin; Ketoconazole; Skin Diseases | 1990 |
10 other study(ies) available for clofazimine and itraconazole
| Article | Year |
|---|---|
Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors.
Topics: 3T3 Cells; Adrenergic Uptake Inhibitors; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding Sites; Biological Transport, Active; Cell Line; Cell Separation; Cell Survival; Flow Cytometry; Fluorescent Dyes; Humans; Inhibitory Concentration 50; Mice; Protein Binding; Reserpine; Spectrometry, Fluorescence; Substrate Specificity; Time Factors | 2001 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Colloid formation by drugs in simulated intestinal fluid.
Topics: Buffers; Chemical Precipitation; Colloids; Intestine, Small; Light; Microscopy, Electron, Transmission; Pharmaceutical Preparations; Scattering, Radiation; Solubility | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
[Sucessful treatment with clofazimine and itraconazole in a 46 year old patient after 32 years duration of disease].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antifungal Agents; Blastomycosis; Clofazimine; Dermatomycoses; Drug Therapy, Combination; Follow-Up Studies; Humans; Itraconazole; Male; Middle Aged; Time Factors | 2002 |
Chromoblastomycosis in a case of borderline lepromatous leprosy with recurrent type II lepra reaction.
Topics: Antifungal Agents; Biopsy; Chromoblastomycosis; Cladosporium; Clofazimine; Humans; Itraconazole; Leprostatic Agents; Leprosy, Borderline; Leprosy, Lepromatous; Male; Treatment Outcome; Young Adult | 2011 |
Case Report: Molecular Confirmation of Lobomycosis in an Italian Traveler Acquired in the Amazon Region of Venezuela.
Topics: Antifungal Agents; Clofazimine; Humans; Italy; Itraconazole; Lacazia; Lobomycosis; Male; Middle Aged; Skin; Travel; Venezuela | 2017 |
Lobomycosis: a therapeutic challenge.
Topics: Adult; Antifungal Agents; Biopsy; Clofazimine; Cryotherapy; Diagnosis, Differential; Ear Diseases; Humans; Itraconazole; Keloid; Lobomycosis; Male; Treatment Outcome | 2018 |